(S)-2,4-diamino-6-((1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile | 1615252-20-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: (S)-2,4-diamino-6-((1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
• 英文别名: 2,4-Diamino-6-{[(1s)-1-(5-Chloro-4-Oxo-3-Phenyl-3,4-Dihydroquinazolin-2-Yl)ethyl]amino}pyrimidine-5-Carbonitrile；2,4-diamino-6-[[(1S)-1-(5-chloro-4-oxo-3-phenylquinazolin-2-yl)ethyl]amino]pyrimidine-5-carbonitrile
• CAS: 1615252-20-4
• 化学式: C₂₁H₁₇ClN₈O
• 分子量: 432.872
• InChiKey: QQBVZBSMGUVONA-NSHDSACASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  31
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  146
• 氢给体数：
  3
• 氢受体数：
  8

文献信息

• PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS
  申请人：Gilead Sciences, Inc.

  公开号：US20150361068A1

  公开（公告）日：2015-12-17

  The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein n, W, A′, B′, R 1 , R 2 , and R 3 are described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3-kinase (PI3K) and are useful for treating conditions mediated by one or more PI3K isoforms. The present application further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts, isomers, tautomer, or mixture thereof, and methods of using these compounds and compositions for treating conditions mediated by one or more PI3K isoforms.

  本申请提供了式（J）的化合物，或其药学上可接受的盐、异构体、互变异构体或其混合物，其中n、W、A′、B′、R1、R2和R3如本文所述。这些化合物是磷脂酰肌醇3-激酶（PI3K）活性的抑制剂，可用于治疗由一个或多个PI3K同工型介导的疾病。本申请还提供了包括式（I）的化合物、或其药学上可接受的盐、异构体、互变异构体或其混合物的药物组合物，以及使用这些化合物和组合物治疗由一个或多个PI3K同工型介导的疾病的方法。
• [EN] PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS<br/>[FR] INHIBITEURS DE PHOSPHATIDYLINOSITOL 3-KINASE
  申请人：GILEAD SCIENCES INC

  公开号：WO2014201409A1

  公开（公告）日：2014-12-18

  The present disclosure provides phosphatidylinositol 3 -kinase (PI3K) inhibitors of formula (I), or pharmaceutically acceptable salts or isomers thereof, in which n, m, R1, R2, R4, and R3 are as defined herein. These compounds are useful for treatment of conditions mediated by one or more PI3K isoforms, such as PI3Kδ. The present disclosure further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts or isomers thereof, and methods of using these compounds and compositions to treat conditions mediated by one or more PI3K isoforms, such as PI3Kδ.

  本公开提供式(I)的磷脂酰肌醇3-激酶（PI3K）抑制剂，或其药学上可接受的盐或异构体，其中n，m，R1，R2，R4和R3如本文所定义。这些化合物可用于治疗由一个或多个PI3K亚型介导的疾病，例如PI3Kδ。本公开还提供包括式(I)的化合物或其药学上可接受的盐或异构体的制药组合物，以及使用这些化合物和组合物治疗由一个或多个PI3K亚型介导的疾病，例如PI3Kδ的方法。
• Phosphatidylinositol 3-kinase inhibitors
  申请人：Gilead Sciences, Inc.

  公开号：US10092563B2

  公开（公告）日：2018-10-09

  The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein W, B, n, m, A′, R1, R2, and R3 are described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3-kinase (PI3K) and are useful for treating conditions mediated by one or more PI3K isoforms. The present application further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts, isomers, tautomer, or mixture thereof, and methods of using these compounds and compositions for treating conditions mediated by one or more PI3K isoforms.

  本申请提供了式 (J) 的化合物、 或药学上可接受的盐、异构体、同分异构体或其混合物，其中 W、B、n、m、A′、R1、R2 和 R3 如本文所述。这些化合物是磷脂酰肌醇 3-激酶（PI3K）活性的抑制剂，可用于治疗由一种或多种 PI3K 同工酶介导的疾病。本申请进一步提供了包括式（I）化合物或其药学上可接受的盐、异构体、同分异构体或混合物的药物组合物，以及使用这些化合物和组合物治疗由一种或多种 PI3K 同工酶介导的病症的方法。
• ISOQUINOLINONE OR QUINAZOLINONE PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS
  申请人：Gilead Calistoga LLC

  公开号：EP2935246B1

  公开（公告）日：2018-07-25
• QUINAZOLINONE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS
  申请人：Gilead Sciences, Inc.

  公开号：EP3154961B1

  公开（公告）日：2019-10-09